Vaccination Against Influenza to Prevent Cardiovascular Events After Acute Coronary Syndromes
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1801 participants.
Also called NCT04001504
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 1,801 participants
- Registry
-
NCT04001504
-
- Other papers using this trial's data
- Influenza vaccination for prevention of death and major cardiovascular events in patients with a history of stroke: A subanalysis of the VIP-ACS trial
- Influenza vaccination strategy in acute coronary syndromes: the VIP-ACS trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Brazil
- Registry status
- Completed
Technical summary
Registry record NCT04001504. Randomized; single masking; primary purpose treatment. Start 2019-07-19 (actual); primary completion 2022-08-28 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Vaccination Against Influenza to Prevent Cardiovascular Events After Acute Coronary Syndromes
- Acronym
- VIP-ACS
- Condition
- Acute Coronary Syndrome
- Intervention (Biological)
- Double Dose Quadrivalent Influenza Vaccine
- Intervention (Biological)
- Standard Dose Quadrivalent Influenza Vaccine
- Lead sponsor
- Hospital Israelita Albert Einstein
- Collaborator
- Ministry of Health, Brazil
Record details
- Record id
cardio:ct-nct04001504- Content hash
0f30214a57530a02753181ad99db21bedb945ef47f8bae844f5f4ec28b9e6a59